Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report

Keyphrases

• Schizophrenia 100%
• Treatment-resistant 100%
• Intravenous Ketamine 100%
• Catatonia 100%
• Ketamine 44%
• Benzodiazepines 22%
• Mutism 22%
• Stupor 22%
• Immobility 22%
• Electroconvulsive Therapy 22%
• Patients with Schizophrenia 22%
• Agitation 11%
• Conventional Treatment 11%
• Young Female 11%
• Therapeutic Potential 11%
• Potential Therapeutics 11%
• Patient Demographics 11%
• Mechanism of Action 11%
• Seizure 11%
• Brain Imaging 11%
• Neurological Disorders 11%
• Psychiatric Conditions 11%
• Life-threatening 11%
• Intravenous Infusion 11%
• Electroencephalogram 11%
• Medical Conditions 11%
• Schizophrenic Patients 11%
• Rapid Recovery 11%
• Psychosis 11%
• Multidrug-resistant 11%
• Haloperidol 11%
• Mood Disorders 11%
• Over 40 11%
• Hallucinations 11%
• Generalized Weakness 11%
• COVID-19 Pandemic 11%
• Psychomotor 11%
• Dissociative Anesthetics 11%

Medicine and Dentistry

• Ketamine 100%
• Catatonia 100%
• Benzodiazepine Derivative 22%
• Stupor 22%
• Mutism 22%
• Electroconvulsive Therapy 22%
• Immobility 22%
• Infusion 11%
• Patient Population 11%
• Epileptic Seizure 11%
• Outpatient 11%
• Apoplexy 11%
• Brain Imaging 11%
• Nervous System Disorder 11%
• Intravenous Drug Administration 11%
• Anesthetic Agent 11%
• Mood Disorder 11%
• Weakness 11%
• Electroencephalogram 11%
• Haloperidol 11%
• Hallucination 11%
• COVID-19 11%

Neuroscience

• Ketamine 100%
• Catatonia 100%
• Mutism 22%
• Stupor 22%
• Electroconvulsive Therapy 22%
• Nervous System Disorder 11%
• Brain Imaging 11%
• Cerebrovascular Accident 11%
• Electroencephalogram 11%
• Haloperidol 11%
• Mood Disorder 11%
• Hallucination 11%
• Dissociative 11%